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Background. The tissue renin-angiotensin system (RAS) may
modulate the structural and functional changes that occur in the
diabetic kidney.
Methods. Hypertensive transgenic (mREN-2)27 rat (TGR) that
exhibit increased tissue renin expression were administered strep-
tozotocin (STZ, diabetic) or citrate buffer (non-diabetic) at six
weeks of age, and sacrificed 4 and 12 weeks later. Further groups
were treated for 12 weeks post-STZ or vehicle with the angioten-
sin converting enzyme inhibitor, perindopril. Comparisons were
made with 18-week-old non-diabetic and diabetic spontaneously
hypertensive rats (SHR).
Results. In diabetic TGR, the most florid lesion was seen after
12 weeks of STZ, with kidneys exhibiting vacuolated tubules,
hylanized arterioles, medullary fibrosis and necrosis and severe
glomerulosclerosis. In contrast, only mild glomerulosclerosis was
seen in non-diabetic TGR and diabetic SHR. Glomerular filtra-
tion rate was increased after four weeks of diabetes in TGR and
12 weeks of diabetes in SHR, but declined by greater than 50%
after 12 weeks of diabetes in TGR. In both TGR and SHR,
diabetes increased albuminuria but did not modify systolic blood
pressure. Renal renin content increased progressively in diabetic
TGR, and this was associated with increased renin immunolabel-
ing in the juxtaglomerular apparatus (JGA) and the appearance of
renin in proximal convoluted tubules. In contrast, renal renin
content and JGA renin immunolabeling were unchanged in
diabetic SHR. Perindopril attenuated renal pathology, improved
renal function and abolished proximal tubular renin immunola-
beling in diabetic TGR.
Conclusions. This is the first report of a diabetic rodent model
developing rapid onset renal impairment. Furthermore, this study
suggests a role for an activated renal RAS in the acceleration of
diabetic renal disease and confirms the benefit of drugs that
inhibit this system.
Chronic diabetes is associated with a progressive alter-
ation in renal structure and function, and is a common
cause of renal failure and vision impairment. Clinical and
experimental evidence have implicated tissue renin-angio-
tensin systems (RAS) in the development of the diabetic
lesions that occur in both the kidney and eye [1–3]. In
humans and most experimental species, renin is synthesized
primarily in the juxtaglomerular cells of the kidney, but has
also been identified in extra-renal tissues such as the eye
and adrenal [4, 5]. The enzyme renin initiates an endocrine
cascade resulting in the formation of the effector peptide,
angiotensin II (Ang II), which has cell specific effects
including the regulation of vascular tone, angiogenesis and
cell growth [6–8].
Plasma prorenin increases in human diabetic nephropa-
thy prior to the onset of microalbuminuria [9, 10]. While it
is unknown if this prorenin is entirely kidney derived [11],
it suggests that the diabetic state is associated with ampli-
fied tissue RAS [3]. Consistent with this concept are reports
that RAS inhibitors are beneficial in reducing the progres-
sion of human and experimental models of diabetic ne-
phropathy [12–15], and also ameliorating glomerular base-
ment membrane (GBM) thickening and increased
glomerular volume in diabetic rats [16]. Although it is
unknown if tissue Ang II is increased in diabetic kidneys,
the beneficial effects of RAS inhibitors on renal function
suggest that Ang II contributes to mesangial expansion and
extracellular matrix (ECM) deposition [17] in the diabetic
kidney, where it may act in synergy with other growth
factors [7, 17].
Evaluation of the tissue RAS in the pathogenesis of
diabetic microvascular complications remains inconclusive
because of the difficulty in obtaining the appropriate
human tissues during the progress of the disease, and
because the laboratory rat, whether normo- or hyperten-
sive, develops only minimal diabetic renal impairment [12,
16]. Rodent resistance to diabetic microvascular pathology
could relate to the levels of tissue renin present in normal
laboratory strains. The transgenic (mREN-2)27 rat (TGR)
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with the mouse Ren-2 gene transfected into the genome of
a Sprague-Dawley rat displays an amplified tissue RAS [18,
19] and greatly enhanced plasma prorenin. This model
offers a unique opportunity to determine whether an
amplified tissue RAS mediates the microvascular compli-
cations in diabetic rats.
METHODS
Research design
Six-week-old female heterozygous TGR (126 6 6 g) and
male spontaneously hypertensive rats (SHR, 125 6 3 g),
received either 55 mg/kg of streptozotocin (STZ; Sigma, St.
Louis, MO, USA) diluted in 0.1 M citrate buffer pH 4.5 or
citrate buffer (non-diabetic) by tail vein injection following
an overnight fast. TGR were studied at 10 and 18 weeks of
age (4 and 12 weeks post-STZ or vehicle) to evaluate the
progression of the kidney disease. A further group of
diabetic and non-diabetic TGR (12 weeks post-STZ or
vehicle) were treated for 12 weeks with an angiotensin
converting enzyme (ACE) inhibitor (perindopril, average
dose 6 mg/kg/day administered within 24 hr of STZ injec-
tion) in their drinking water. Comparisons were made with
18-week-old (12 weeks post-STZ or vehicle) diabetic and
non-diabetic SHR. All rats were allowed free access to tap
water and standard rat chow containing 0.25% Na1 and
0.76% K1 (GR2; Clark-King & Co., Gladesville, NSW,
Australia). Each week, rats were weighed and blood glu-
cose (non-diabetic, 4 to 8 mmol/liter; diabetic, 18 to 22
mmol/liter) was estimated using an AMES glucometer.
Every four weeks, systolic blood pressure (SBP) was re-
corded in conscious rats by tail plethysmography. Diabetic
rats received a daily injection of insulin (2 to 4 units i.p.;
Ultratard, Novo Nordisk, Denmark) to promote weight
gain and to reduce mortality. Experimental procedures
adhered to the guidelines of the National Health and
Medical Research Council of Australia’s Code for the Care
and Use of Animals for Scientific Purposes and were
approved by the Bioethics Committee of the University of
Melbourne.
Renal functional and biochemical studies
Glomerular filtration rate. Glomerular filtration rate
(GFR) was determined in all rats (N 5 6 rats per group)
prior to sacrifice by a single injection isotopic method [20].
The isotope 99technetium-diethylene triamine penta-acetic
acid (99Tc-DTPA) was injected into the tail vein and blood
was sampled after 43 minutes. Plasma radioactivity was
measured and compared with a reference prepared at the
time of injection. GFR was calculated as clearance 5 V 3
In(P0/Pt)/t, where V is the estimated volume of distribution,
P0 the theoretical plasma space concentration at injection,
and Pt is the observed plasma concentration t minutes after
injection [20].
Albumin excretion rate and electrolyte output. TGR (0, 4, 8
and 12 weeks post-STZ or vehicle, N 5 6 rats per group)
and SHR (12 weeks post-STZ or vehicle, N 5 6 rats per
group) were housed in metabolic cages for 24 hours to
measure fluid intake and urinary output of Na1, K1 and
albumin. Animals continued to have free access to tap
water and standard laboratory chow during this period.
Urinary Na1 and K1 concentrations were measured using
an IL 943 flame photometer (Instrumentation Laborato-
ries, Milan, Italy). Albumin concentration was determined
from an aliquot of urine by a double antibody radioimmu-
noassay as previously described [21].
Plasma for electrolytes and renin assay. Prior to sacrifice,
plasma samples (100 ml) were collected in heparinized vials
(10 units/ml) from the tail vein of conscious rats (N 5 6 rats
per group). The blood samples were centrifuged at 2000 3
g for five minutes at 4°C and the plasma supernatant
removed and frozen for estimations of Na1 and K1 (IL 943
flame photometer) and total and active renin. Samples with
obvious hemolysis were not included in the study.
Tissue and plasma renin assay
Rats (N 5 6 per group) were anesthetized (Nembutal 60
mg/kg body wt i.p.; Boehringer Ingelheim, Australia) and
perfused via the abdominal aorta with 0.1 M phosphate
buffered saline (PBS), pH 7.4 at 180 to 220 mm Hg for one
to two minutes to remove circulating blood [5]. Kidneys
were rapidly removed and snap frozen in liquid nitrogen.
The left kidney was frozen in 1 ml of 0.1 M PBS at pH 7.4,
homogenized and refrozen twice before assay of total
renin. Prorenin estimation was not attempted in kidneys
since satisfactory inhibition of processing and other activat-
ing enzymes during extraction and assay of renal tissue has
never been achieved.
Plasma and kidney samples were assayed for renin by the
enzyme kinetic method with hog renin as the reference
standard and 24-hour nephrectomized rat plasma as the
angiotensinogen substrate in the presence of protease
inhibitors. Duplicate samples were incubated (0.5 hr at
37°C, pH 7.4) with an adequate concentration of angio-
tensinogen (1 mmol/liter) and the renin present in the
samples was estimated by immunoassay of generated an-
giotensin I referenced against the amount of angiotensin I
generated by 2 3 1026 Goldblatt units (GU) of hog renin
(National Standards Laboratory, Holy Hill, London, UK).
The plasma concentration of total renin was assayed after
activation of prorenin by trypsin treatment (2 mg/ml for 10
min on ice) as applied in previous studies in the mouse and
rat [5].
Tissue fixation
Separate groups of rats (N 5 6 rats per group) were used
for morphological studies. These rats were anesthetized
and perfusion fixed [5] with 4% paraformaldehyde in 0.1 M
phosphate buffer at pH 7.4. After five minutes of vascular
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perfusion (100 to 200 ml of fixative), kidneys were removed
and sliced transversely. Kidneys were post-fixed for two
hours, routinely processed, embedded in paraffin and sec-
tioned at 3 mm.
Histopathology
In all rats changes in structure were assessed in at least
25 randomly selected kidney sections (N 5 6 per group).
Sections were stained with either hematoxylin and eosin (H
& E) to examine cell structure, periodic acid-Schiff’s (PAS)
to identify changes in basement membrane architecture
and glycogen deposition, or Masson’s modified trichrome
to demonstrate collagen matrix [22].
Glomerulosclerotic index. In kidney sections stained with
PAS, 150 to 200 glomeruli from all rats were examined
(N 5 6 per group). The degree of sclerosis in each
glomerulus was subjectively graded on a scale of 0 to 4 by
the method of Saito et al [23]: Grade 0 5 normal; Grade
1 5 sclerotic area up to 25% (minimal); Grade 2 5
sclerotic area 25 to 50% (moderate); Grade 3 5 sclerotic
area 50 to 75% and Grade 4 5 sclerotic area 75 to 100%
(severe). Glomerulosclerosis was defined as GBM thicken-
ing, mesangial hypertrophy and capillary occlusion. An
index of sclerosis (I.S.) was then calculated using the
formula:
I.S. 5 ~1 3 n1) 1 (2 3 n2) 1 (3 3 n3) 1 (4 3 n4)/n0 1 n1
1 n2 1 n3 1 n4
where nx 5 number of glomeruli in each grade of glomer-
ulosclerosis.
Association of glomerulosclerosis with renin-labeled juxta-
glomerular apparatus (JGA). At least five randomly selected
sections from diabetic and non-diabetic (12 weeks post-
STZ or vehicle) TGR kidneys (N 5 6) were immunolabeled
for renin and counterstained with PAS. A minimum of 50
glomeruli, which displayed the afferent arteriole entering
the glomerulus, were examined for renin immunolabeling.
At the same time sclerosis in each glomerulus was graded
as described above.
Immunohistochemistry
Sections from both kidneys of all rats were incubated for
20 minutes with normal goat serum (NGS) diluted 1:10
with 0.1 M PBS at pH 7.4 (N 5 6 rats per group). Sections
were then incubated for 18 hours at 4°C with polyclonal
antisera raised in rabbits to either purified mouse submax-
illary renin protein, a rat renin fusion protein, or to
oligopeptides of the mouse and rat renin prosequence as
previously detailed [5, 24, 25]. Sections incubated with 1:10
NGS instead of the primary antiserum served as the
negative control. After thorough washing with PBS (3 3 5
min changes), the sections were flooded with a solution of
5% hydrogen peroxide, rinsed with PBS (2 3 5 mins) and
incubated with biotinylated goat anti-rabbit IgG (Dako-
patts, Glostrup, Denmark) or biotinylated goat anti-sheep
IgG (Zymed Laboratories, San Francisco, CA, USA) di-
luted 1:200 with PBS. Sections were rinsed with PBS (2 3
5 min) and incubated with an avidin-biotin peroxidase
complex (Vector, Burlingame, CA, USA) diluted 1:200
with PBS. Following rinsing with PBS (2 3 5 min), sections
were incubated with 0.05% diaminobenzidine and 0.05%
hydrogen peroxide (Pierce, Rockford, IL, USA) in PBS at
pH 7.6 for one to three minutes, rinsed in tap water for five
minutes, counterstained in Mayer’s hematoxylin, differen-
tiated in Scott’s tap water, dehydrated, cleared and
mounted in Depex.
Statistics
Comparisons between non-diabetic and diabetic TGR
and SHR were analyzed with a two-way ANOVA followed
by a Tukey’s post hoc comparison. All statistics were
performed using Microsoft Minitab version 10.5. A change
was considered statistically significant if P , 0.05. All
values are expressed as means 6 SEM unless otherwise
stated.
RESULTS
Renal functional and biochemical studies
After 12 weeks of diabetes, body weights were signifi-
cantly lower than that of age-matched non-diabetic rats and
diabetic TGR treated with perindopril (Table 1). Perindo-
pril treatment reduced SBP in non-diabetic and diabetic
TGR and there was no significant difference between the
SBP of non-diabetic and diabetic rats. Plasma glucose was
elevated to the same extent in diabetic rats when compared
to non-diabetic rats. By 12 weeks the diabetic TGR had
elevated plasma K1, which was not observed in either
non-diabetic TGR, diabetic TGR treated with perindopril
or non-diabetic and diabetic SHR (Table 1). Plasma Na1
was not altered with diabetes. Diabetic rats had increased
urinary excretion of Na1 and K1 when compared to
non-diabetic rats, and this was not influenced by perindo-
pril therapy in TGR (Table 1).
Renal parameters. Urinary albumin excretion increased
progressively over the 12 week period in the diabetic TGR
(Fig. 1) and this was markedly ameliorated by perindopril
treatment. Diabetes was also associated with increased
urinary albumin in SHR (5 3/4 1.1 mg/24 hr) when
compared to non-diabetic SHR (0.8 3/4 1.1 mg/24 hr, P ,
0.05). The GFR of TGR is presented in Figure 2. After four
weeks of diabetes GFR was significantly higher than for
matched non-diabetic TGR. By 12 weeks, GFR declined in
diabetic TGR and was significantly lower than non-diabetic
TGR and non-diabetic TGR treated with perindopril. The
decline in GFR observed in diabetic TGR was attenuated
with perindopril treatment. By contrast, after 12 weeks of
diabetes SHR had an elevated GFR (2.6 6 0.2 ml/min)
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when compared to non-diabetic SHR (1.5 6 0.1 ml/min,
P , 0.05).
The kidney weight after four weeks of diabetes in TGR
(1.79 6 0.45 g) was significantly higher than non-diabetic
TGR (1.56 6 0.41 g, P , 0.05). After 12 weeks of diabetes
in TGR there was no significant difference in kidney
weights (non-diabetic, 1.96 6 0.51 g; diabetic, 2.01 6
0.63 g). With perindopril treatment in TGR there was no
significant difference in kidney weights between non-dia-
betic (1.91 6 0.47 g) and diabetic (1.92 6 0.48 g) TGR. In
diabetic (1.58 6 0.23 g) SHR, the kidney weights were
higher than non-diabetic (1.25 6 0.23 g) SHR.
Kidney and plasma renin assay
Kidney renin. In diabetic TGR, kidney renin content was
progressively increased when compared to non-diabetic
Fig. 1. Albuminuria in non-diabetic transgenic m(Ren-2)27 rats (TGR,
M), non-diabetic TGR rats treated with perindopril (P, f), diabetic TGR
(E) and diabetic TGR treated with perindopril (P, F) from 0 to 12 weeks.
Values are expressed as geometric means 3/4 tolerance factors. N 5 6.
*P , 0.05 compared to non-diabetic, #P , 0.05 compared to diabetic
treated with perindopril.
Fig. 2. Glomerular filtration rate in non-diabetic transgenic m(Ren-2)27
rats (TGR, M), non-diabetic TGR treated with perindopril (P, f), diabetic
TGR (E) and diabetic TGR treated with perindopril (P, F) from 0 to
12 weeks. Values are expressed as means 6 SEM. N 5 6. *P , 0.05
compared to non-diabetic, #P , 0.05 compared to diabetic treated with
perindopril.
Table 1. Body weight, systolic blood pressure, and biochemistry of non-diabetic and diabetic transgenic m(Ren-2)27 (TGR) and spontaneously
hypertensive rats (SHR)
Body wt
g
SBP
mm Hg
Plasma mmol/liter Urine mmol/min
Glucose Na K Nav Kv
0 weeks
Non-diabetic TGR 126 6 6 140 6 11 6.3 6 0.4 139 6 4 4.70 6 0.20 0.55 6 0.10 1.13 6 0.10
4 weeks
Non-diabetic TGR 236 6 4 164 6 4 6.2 6 0.6 139 6 4 4.67 6 0.20 0.64 6 0.10 1.46 6 0.20
Non-diabetic TGR1 P 222 6 2 133 6 3b 5.6 6 0.3 134 6 3 5.10 6 0.30 0.70 6 0.20 1.49 6 0.20
Diabetic TGR 191 6 11a 166 6 5 19.9 6 0.7a 136 6 3 5.12 6 0.10 1.27 6 0.20a 2.76 6 0.40a
Diabetic TGR 1 P 210 6 4 117 6 9ab 20.1 6 0.4ab 139 6 3 4.40 6 0.20 1.30 6 0.30ab 2.8 6 0.40ab
12 weeks
Non-diabetic TGR 288 6 10 216 6 9 5.5 6 0.3 140 6 3 4.55 6 0.20 1.29 6 0.20 2.37 6 0.40
Non-diabetic TGR1 P 310 6 5 166 6 7b 5.6 6 0.4 131 6 1 5.26 6 0.10 1.30 6 0.20 2.46 6 0.30
Diabetic TGR 224 6 8a 229 6 7 20.7 6 1.0a 143 6 2 6.71 6 0.30a 2.58 6 0.40a 4.40 6 0.50a
Diabetic TGR 1 P 268 6 7a 139 6 3ab 19.7 6 0.4a 132 6 4 4.20 6 0.10b 2.70 6 0.30a 4.60 6 0.40a
Non-diabetic SHR 331 6 7 187 6 5 4.9 6 0.2 139 6 1 4.80 6 0.20 0.54 6 0.10 0.86 6 0.10
Diabetic SHR 307 6 5a 181 6 9 21.8 6 0.6a 139 6 1 4.90 6 0.20 0.83 6 0.14a 1.67 6 0.15a
Values are expressed as means 6 SEM. N 5 6 rats per group. Perindopril (P) was given in drinking water from week 0 (6 weeks of age).
a P , 0.05, non-diabetic versus diabetic.
b P , 0.05, untreated versus perindorpil treated.
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TGR (Fig. 3). Perindopril treatment increased renal renin
content in both non-diabetic and diabetic TGR (Fig. 3; P ,
0.05). In contrast, kidney renin was not altered by diabetes
in SHR (non-diabetic, 1.20 6 0.43 GU/kidney; diabetic,
1.30 6 0.28 GU/kidney).
Plasma renin. Non-diabetic TGR had high plasma pro-
renin levels. After four weeks of diabetes in TGR, plasma
renin was still mainly in the pro-form, although both total
and prorenin levels were less than those of non-diabetic
TGR. By contrast, after 12 weeks of diabetes in TGR,
plasma renin was all active with no prorenin detectable, and
plasma active renin levels were markedly elevated when
compared to non-diabetic TGR. Perindopril treatment
selectively increased plasma active renin in diabetic TGR
with prorenin again below threshold (Table 2). Plasma
renin in SHR was predominantly active and diabetes had
no effect on plasma renin levels (Table 2).
Histopathology and renin immunohistochemistry of the
kidney
TGR after four weeks of STZ or vehicle. Non-diabetic
TGR and diabetic TGR displayed no renal pathology or
renin protein and renin prosequence labeling (not shown).
TGR after 12 weeks of STZ or vehicle. In the kidney cortex
of non-diabetic TGR (Fig. 4A), some glomeruli were
sclerotic (Table 3) and occasional JGAs were renin positive
(Fig. 4B). In contrast, in diabetic TGR (Fig. 4 C, D, E),
many efferent arterioles were hyalanized and most glomer-
uli displayed thickened GBM, mesangial hypertrophy and
occluded glomerular capillary lumens. In 3 of the 12
kidneys examined there was evidence of focal glomerulo-
sclerosis. Distal tubules and macula densae were often
vacuolated and degenerated (Fig. 4 C, D, E) and some
distal tubules, proximal convoluted tubules and collecting
ducts contained glycogen deposits (Armanni-Ebstein le-
sions, Fig. 4D). Intense labeling for renin protein (Fig. 4C)
and weak labeling for renin prosequence (Fig. 4D) was
seen in the wall of the afferent arteriole. Also, intense
labeling for renin protein but not renin prosequence was
detected in the cytoplasm of many proximal tubules of
diabetic TGR (Fig. 4F) but not non-diabetic TGR (Fig.
4B). Perindopril treatment ameliorated the glomerular and
tubular pathology (Fig. 4G), although some tubules still
contained glycogen and there was no evidence of focal
glomerulosclerosis. In addition, perindopril abolished renin
protein labeling in proximal tubules (Fig. 4H).
Kidney medullae from non-diabetic TGR had no struc-
tural changes in tubules or in the tubulointerstitium (Fig. 5
A, B). In contrast in the medulla of diabetic TGR, tubules
were often dilated and necrotic (Fig. 5 C, D) and there was
a well developed inflammatory reaction within tubules and
the surrounding interstitium (Fig. 5C). In diabetic TGR,
both the cortical and medullary interstitium stained more
extensively for collagen (Fig. 5C) than non-diabetics (Fig.
5A). The inner medulla was necrosed in 2 of the 12 diabetic
TGR kidneys. With perindopril treatment, the tubular
damage, inflammatory reaction and medullary interstitial
fibrosis were prevented (Fig. 5 E, F).
SHR after 12 weeks of STZ or vehicle. The only change in
renal architecture in diabetic SHR was minimal thickening
of GBM and mesangial expansion compared with non-
diabetics (not shown). Immunolabeling for renin protein
Fig. 3. Kidney renin content in diabetic (f) and non-diabetic (M)
transgenic m(Ren-2)27 (TGR; 4 and 12 weeks post-STZ or vehicle, with
and without perindopril (P) treatment for 12 weeks) rats. Symbols are:
(^) non-diabetic 1 P; (s) diabetic 1 P. Values are expressed as means 6
SEM. N 5 6. GU is Goldblatt units. *P , 0.05 compared to the respective
non-diabetic group.
Table 2. Plasma renin in non-diabetic and diabetic transgenic m(Ren-
2)27 and spontaneously hypertensive rats
Total Active Prorenin
mGU/ml
4 weeks
Non-diabetic TGR 6.40 6 0.78 0.20 6 0.01 6.20 6 0.77
Diabetic TGR 4.70 6 0.80a 0.12 6 0.03 3.90 6 1.00a
12 weeks
Non-diabetic TGR 4.90 6 0.40 0.20 6 0.02 4.70 6 0.40
Non-diabetic TGR 1 P 10.55 6 0.96b 0.53 6 0.13b 10.00 6 0.97b
Diabetic TGR 6.70 6 1.60 6.70 6 1.60a 0a
Diabetic TGR 1 P 11.35 6 2.00b 11.35 6 2.00ab 0a
Non-diabetic SHR 0.53 6 0.28 0.50 6 0.28 0.03 6 0.01
Diabetic SHR 0.44 6 0.27 0.40 6 0.28 0.03 6 0.01
Values are expressed as means 6 SEM; N 5 6. Abbreviations are:
transgenic m(Ren-2)27 rat (TGR), spontaneously hypertensive rats
(SHR), Goldblatt units (GU), perindopril (P).
a P , 0.05 non-diabetic versus diabetic
b P , 0.05 untreated versus perindopril treated.
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Fig. 5. Three micrometer paraffin sections of kidney medulla from diabetic and non-diabetic transgenic m(Ren-2)27 (TGR; 12 weeks post-STZ or
vehicle) rats. A, C and E are cross sections of the inner stripe of the outer medulla stained with Masson’s trichrome. B, D and F are longitudinal sections
of the inner stripe of the outer medulla stained with PAS. Abbreviations are: VR, vasa recta bundle; T, medullary tubules. In non-diabetic TGR (A,
B) no pathology was observed, while in diabetic TGR (C, D) tubules were dilated (C) and vasa recta degenerated (D). The interstitium was fibrotic and
appeared to contain more collagen (stained blue), and inflammatory cells (C, arrow) were apparent. Perindopril prevented the tubular and interstitial
pathology (E, F). Magnification 3 380.
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Fig. 4. Three-micrometer paraffin sections of kidney cortex from diabetic and non-diabetic transgenic m(Ren-2)27 (TGR; 12 weeks post-STZ or
vehicle) rats showing histology and the distribution of renin immunolabeling. A is stained with PAS. C, D, E and G are immunolabeled with renin
protein or renin prosequence and counterstained with PAS. B, F and H are immunolabeled for renin protein and counterstained with Mayer’s
hematoxylin. Abbreviations are: G, glomerulus; DT, distal tubule; PT, proximal tubule. In non-diabetic TGR (A,B) some glomeruli had thickened GBM
(A) and renin protein labeling (B, arrow) was occasionally seen in the wall of the afferent arteriole as it penetrated the glomerulus. In diabetic TGR
(C, D, E), many tubules were vacuolated and degenerated (C, D, E arrow) and some undamaged tubules contained glycogen (E, asterisk), which was
more apparent at a higher magnification. Efferent arterioles were often hyalanized (E, asterisk) and most glomeruli exhibited thickened GBM. Most
afferent arterioles were intensely labeled for renin protein (C, double arrows) and weakly labeled for renin prosequence (D, double arrows) with renin
protein labeling also detected in PT (F, arrow) but not non-diabetic TGR (B). Perindopril attenuated the glomerular and prevented the tubular lesions
in diabetic TGR (G), abolished renin labeling in PT (H). Magnification 3 300.
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and renin prosequence was confined to the juxtaglomerular
cells in the wall of the afferent arteriole, closely associated
with the glomerulus, and this pattern and intensity of
labeling did not alter with diabetes (not shown).
Glomerulosclerotic Index. At four weeks post-STZ or
vehicle no glomerulosclerosis was observed in non-diabetic
or diabetic TGR. By 12 weeks, 41% of glomeruli were
normal in non-diabetic TGR but only 18% in diabetic TGR
(Table 3). Also, 27% of diabetic TGR glomeruli were
severely sclerosed (Grades 3 and 4) compared with only 3%
of non-diabetic TGR. With perindopril treatment 99% of
glomeruli were either normal or moderately sclerosed
(Grades 1 and 2). By contrast, there was minimal evidence
of glomerulosclerosis in diabetic SHR (Table 3).
Association of glomerulosclerosis with renin-labeled JGA.
In non-diabetic and diabetic TGR, 31 to 85% of grade 1
and all grade 2 to 4 sclerotic glomeruli were associated with
renin immunolabeling in the JGA, whereas in non-sclerotic
glomeruli there was no renin immunolabeling detected in
the JGA.
DISCUSSION
This study provides the first evidence for a rodent model
of diabetic nephropathy that develops severe renal impair-
ment resembling human diabetic renal failure [26, 27].
After only 12 weeks of STZ diabetes in the TGR, there was
a decline in GFR concomitant with advanced glomerulo-
sclerosis, tubulointerstitial damage, albuminuria, and in
some animals medullary necrosis. This is in contrast to
other short- and long-term diabetic rodent models, which
exhibit structural and functional changes that mimic only
the early phase of human diabetes [12, 16]. Unlike these
models, which have minimal GBM thickening and mesan-
gial expansion, over 80% of glomeruli in the diabetic TGR
were sclerotic with 27% severely sclerotic. In a subgroup of
diabetic TGR, focal glomerulosclerosis was detected, rem-
iniscent but not directly comparable to Kimmelsteil-Wilson
nodules of human nephropathy [28]. In addition, like
human diabetic renal failure, glomerular function became
compromised, with renal hyperfiltration at four weeks
progressing to a 50% decline in GFR by 12 weeks of
diabetes in TGR. This pattern parallels the serial changes
observed in human diabetes [27]. In contrast to diabetic
humans and TGR, GFR remains elevated in other diabetic
rodents, suggesting resistance to diabetic renal failure [12].
To minimize blood pressure effects on the lesion, diabe-
tes was induced in young female heterozygous TGR before
they had fully established hypertension [19], and kidneys
were examined prior to the development of the hyperten-
sion related disease that occurs in TGR [29]. It should be
noted that even at 6 to 8 months of age only a small number
of glomeruli are severely affected in the non-diabetic TGR
kidney [29], and in our study in 12-week-old female het-
erozygous non-diabetic TGR, only 3% of glomeruli showed
severe sclerosis. The pathology observed in the non-dia-
betic TGR may be related to the increased GFR when
compared to age-matched non-diabetic SHR. Despite the
age-related change in kidney structure and function in
non-diabetic TGR, the kidney disease in diabetic TGR was
more marked than in SHR, which also had systemic
hypertension. In the present study it was clearly evident on
light microscopy that there were similarities between the
morphology of human and experimental diabetic nephrop-
athy. This included mesangial expansion and GBM thick-
ening. It would be interesting to explore the earliest
morphological changes in the kidney in these TGR before
the lesions are clearly detectable on light microscopy using
stereological techniques at the electron microscope level.
The most obvious difference between diabetic TGR and
other rodent models of diabetes is the presence of an
enhanced tissue RAS. Conflicting evidence with respect to
the kidney RAS in experimental diabetes comes from
studies in rats, which have shown variously increases in
kidney renin content [3], renin mRNA [3, 30] and angio-
tensinogen expression [3], or contrarily, decreases or no
alterations [31, 32]. With respect to the non-diabetic TGR,
renin is mainly expressed in extra-renal tissues [19], with
kidney renin expression [19], content and the number of
renin labeled JGA low compared with normal SDR (un-
published observations). Despite this, the actual kidney
Ang II level is increased [33], which suggests that in the
TGR there is enhanced conversion of angiotensinogen to
angiotensin I by mouse renin [34] or that the Ang II is of
extra-renal origin. Irrespective of the activity status of the
renal RAS in non-diabetic TGR, diabetes was associated
with a progressive increase from 4 to 12 weeks in renal
Table 3. Glomerulosclerotic index and the percentage of glomerulosclerosis in kidneys from diabetic and non-diabetic (12 weeks post STZ or
vehicle) transgenic m(Ren-2)27 and spontaneously hypertensive rats.
GSI Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Non-diabetic TGR 0.86 6 0.10 41 6 5 34.8 6 4 21 6 3 3.2 6 1 0
Diabetic TGR 1.68 6 0.10a 17.8 6 3 29.7 6 5 25.8 6 2 20 6 3 6.7 6 2
Diabetic TGR 1 P 0.67 6 0.02 44.3 6 2 44.8 6 2 10.7 6 0.9 0.20 6 0.1 0
Non-diabetic SHR 0.05 6 0.02 96 6 2 4 6 2 0 0 0
Diabetic SHR 0.16 6 0.07a 85 6 4 13 6 4 2 6 1 0 0
Values are expressed as means 6 SEM; N 5 6. Abbreviations are: Transgenic m(Ren-2)27 rat (TGR), spontaneously hypertensive rat (SHR),
glomerulosclerotic index (GSI), perindopril (P).
a P , 0.01, when compared to respective non-diabetic group
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renin content and the percentage of renin labeled JGA.
This rise in renal renin, and the association of renin
containing cells with moderately or severely sclerotic glo-
meruli supports a local paracrine causative role for tissue
RAS in the development of diabetic glomerulosclerosis.
Moreover, it is of particular interest that after 12 weeks of
diabetes in TGR, there was complete conversion of plasma
prorenin to active renin that may further accelerate Ang II
formation in this model. By contrast, the SHR has low
renin and Ang II levels [35] and does not develop advanced
glomerulosclerosis.
There is considerable evidence that Ang II has mitogenic
and cellular growth promoting properties, and causes hy-
pertrophy of glomerular mesangial cells and increases the
production of ECM proteins [17]. This is associated with
increased expression of transforming growth factor-b
(TGF-b) [17], a cytokine that plays a pivotal role in kidney
disease since it apparently regulates the glomerular pro-
duction of ECM proteins and promotes tubulointerstitial
disease [36, 37]. In STZ diabetes, TGF-b expression and
immunolabeling are increased in mesangial cells and cor-
tical tubules [37–39]. It is therefore feasible that in human
and experimental diabetes, up-regulation of the kidney
RAS results in increased local production of Ang II that
either alone or synergistically with other local growth
factors provokes proliferative and sclerotic renal lesions.
The TGR model would be ideal to further assess the
inter-relationships between the RAS, growth factors such
as TGF-b, and ultimately matrix protein deposition. Re-
cent studies have shown in both the renal ablation model
and in the diabetic SDR that ACE inhibition and angio-
tensin type 1 receptor blockade (AT1) leads not only to
decreased TGF-b expression, but also to decreased colla-
gen deposition [36, 37].
Blockade of the RAS with AT1 or ACE inhibitors
reduces detrimental glomerular changes (that is, increased
glomerular pressure and volume) in human and rodent
diabetic nephropathy [12–15]. The present study is the first
to report the effect of ACE inhibition on a rodent model of
advanced diabetic nephropathy. Perindopril treatment suc-
cessfully attenuated the severe glomerulosclerosis, tubular
vacuolation, interstitial fibrosis and albuminuria in the
diabetic TGR. Furthermore, the associated decline in GFR
was reduced. These findings support a role for enhanced
tissue RAS in mediating diabetic microvascular kidney
disease, and confirm the renoprotective effects of ACE
inhibitors. However, to further separate the role of systemic
hypertension and the intra-renal RAS, direct comparisons
with equally anti-hypertensive regimens are required. This
is difficult to perform since the hypertension in the TGR is
primarily Ang II dependent [19].
The novel finding of immunolabeling for renin in proxi-
mal convoluted tubules of diabetic TGR provides support
for the concept of a local nephron diabetes-induced en-
hancement of the RAS being causally related to the renal
lesions. All components of the RAS have been identified
within proximal tubules [40], however, the only reported
change in the tubular RAS in diabetes has been a decrease
in ACE immunolabeling [3]. The extensive labeling for
renin in the cytoplasm of intact proximal tubule cells of
diabetic TGR may represent increased local synthesis or
alternatively, renin secreted from the hypertrophic JGA
passing through a leaky glomerular filtration barrier with
subsequent reabsorption. It is relevant that ACE inhibition
increased plasma and renal renin levels even further, but
caused proximal tubule renin to disappear, making filtra-
tion and reabsorption an unlikely explanation. Whatever
the genesis of the tubular renin, the finding of renin at this
site is further evidence of widespread activation of the renal
RAS by the diabetic process. It is possible that this increase
in proximal tubule renin leads to Ang II formation and
represents an important mechanism for tubulointerstitial
disease. It would be helpful to assess the status of the RAS
in the diabetic TGR kidney in more detail. This is likely to
be rather complex as the distribution of the components of
the RAS are altered with diabetes [3]. Tissue Ang II levels
and renin and Ang II immuno-electron microscopy and in
situ hybridization studies will be required to resolve these
questions and are presently under investigation.
In summary, the diabetic TGR is the first rapid-onset
rodent model of severe renal disease that mimics the
progressive pathological and functional changes seen in
human diabetic nephropathy. Furthermore, the indices of
renal RAS are markedly activated and perindopril treat-
ment ameliorates the developing kidney lesion. These
findings implicate a role for an enhanced renal RAS in the
pathogenesis of progressive diabetic nephropathy and are
of relevance to our further understanding of the renopro-
tective effects of ACE inhibitors.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; Ang II, angiotensin II; AT1, angiotensin type 1 receptor; ECM,
extracellular matrix; GBM, glomerular basement membrane; GFR, glo-
merular filtration rate; GU, Goldblatt unit; JGA, juxtaglomerular appa-
ratus; PAS, periodic acid Schiff; PBS, phosphate buffered saline; RAS,
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renin-angiotensin system; SBP, systolic blood pressure; SHR, spontane-
ously hypertensive rat; STZ, streptozotocin; 99Tc-DTPA, 99technetium-
diethylene triamine penta-acetic acid; TGF-B, transforming growth fac-
tor-b; TGR, transgenic (mREN-2)27 rat.
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